HCP | Theracim Attributes
Less immunogenic than the murine antibody
Lower incidence of hypersensitivity
Intermediate affinity binding
Good safety profile
The humanized antibody is remarkably less immunogenic than the murine antibody.
Hypersensitivity reactions are rare after nimotuzumab treatment, due to a low anti-idiotypic response to the antibody.
Pre-medication for hypersensitivity is generally not required
TheraCIM binds to EGFR with intermediate affinity 108 and 109 M causing high tumour uptake and low uptake in normal tissue. This results in effective EGFR blockade without causing deleterious effects on the skin, because the optimal dose is far lower than the toxic dose.
Pre-laboratory monitoring before TheraCIM is generally not required
Well tolerated: In particular indications, TheraCIM can be use in longer duration for mainstay therapy.
TheraCIM is administered intravenously for 30-60 minutes.
TheraCIM does not need a loading dose.
TheraCIM has standard dose per patient.